Home LiteratureArticle Details
PMID: 18419775 Published · ppublish English Journal Article Research Support, N.I.H., Extramural

Conserved and non-conserved features of HIV-1 and SIVagm Vif mediated suppression of APOBEC3 cytidine deaminases.

Cellular microbiology ·Vol. 10 ·No. 8 ·2008-08-00 ·Pages 1662-75

Zhang W, Huang M, Wang T, Tan L, Tian C, Yu X, Kong W, Yu XF

Abstract

Human cytidine deaminase APOBEC3C (A3C) acts as a potent inhibitor of SIVagm and can be regulated by both HIV-1 and SIVagm Vif. The mechanism by which Vif suppresses A3C is unknown. In the present study, we demonstrate that both HIV-1 and SIVagm Vif can act in a proteasome-dependent manner to overcome A3C. SIVagm Vif requires the Cullin5-ElonginB-ElonginC E3 ubiquitin ligase for the degradation of A3C as well as the suppression of its antiviral activity. Mutation of a residue critical for the species-specific recognition of human or monkey A3G by HIV-1 Vif or SIVagm Vif in A3C had little effect on HIV-1 or SIVagm Vif-mediated degradation of A3C. Although the amino-terminal region of A3G was not important for Vif-mediated degradation, the corresponding region in A3C was critical. A3C mutants that were competent for Vif binding but resistant to Vif-mediated degradation were identified. These data suggest that primate lentiviral Vif molecules have evolved to recognize multiple host APOBEC3 proteins through distinct mechanisms. However, Cul5-E3 ubiquitin ligase appears to be a common pathway hijacked by HIV-1 and SIV Vif to defeat APOBEC3 proteins. Furthermore, Vif and APOBEC3 binding is not sufficient for target protein degradation indicating an important but uncharacterized Vif function.

MeSH Terms
APOBEC Deaminases Animals Cell Line Cullin Proteins/metabolism Cytidine Deaminase Cytosine Deaminase/metabolism Gene Products, vif/genetics,metabolism HIV-1/metabolism Haplorhini Humans Models, Molecular Proteasome Endopeptidase Complex/metabolism Simian Immunodeficiency Virus/metabolism Species Specificity vif Gene Products, Human Immunodeficiency Virus/genetics,metabolism
Chemicals
CUL5 protein, human Cullin Proteins Gene Products, vif vif Gene Products, Human Immunodeficiency Virus Proteasome Endopeptidase Complex Cytosine Deaminase APOBEC Deaminases APOBEC3 protein, human Cytidine Deaminase
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Zhang Wenyan
College of Life Science, Jilin University, Changchun 130021, China.
Huang Michael
Wang Tao
Tan Lindi
Tian Chunjuan
Yu Xianghui
Kong Wei
Yu Xiao-Fang
References (75)
75 references, click to expand
  1. Inhibition of hepatitis B virus replication by APOBEC3G.
    Science. 2004 Mar 19;303(5665):1829 PMID: 15031497
  2. Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging.
    J Virol. 2004 Nov;78(21):11841-52 PMID: 15479826
  3. Differential inhibition of long interspersed element 1 by APOBEC3 does not correlate with high-molecular-mass-complex formation or P-body association.
    J Virol. 2007 Sep;81(17):9577-83 PMID: 17582006
  4. Innate cellular defenses of APOBEC3 cytidine deaminases and viral counter-defenses.
    Curr Opin HIV AIDS. 2006 May;1(3):187-93 PMID: 19372807
  5. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.
    J Virol. 2006 Sep;80(17):8450-8 PMID: 16912295
  6. Hypermutation of HIV-1 DNA in the absence of the Vif protein.
    Science. 2003 May 16;300(5622):1112 PMID: 12750511
  7. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif).
    Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3927-32 PMID: 14978281
  8. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
    Nature. 2003 Jul 3;424(6944):99-103 PMID: 12808466
  9. Intrinsic immunity: a front-line defense against viral attack.
    Nat Immunol. 2004 Nov;5(11):1109-15 PMID: 15496950
  10. The interaction between HIV-1 Gag and APOBEC3G.
    J Biol Chem. 2004 Aug 6;279(32):33177-84 PMID: 15159405
  11. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines.
    Genes Dev. 2004 Dec 1;18(23):2867-72 PMID: 15574593
  12. APOBEC3 proteins inhibit human LINE-1 retrotransposition.
    J Biol Chem. 2006 Aug 4;281(31):22161-22172 PMID: 16735504
  13. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome.
    Nat Struct Mol Biol. 2004 May;11(5):435-42 PMID: 15098018
  14. Cytidine deaminase APOBEC3B interacts with heterogeneous nuclear ribonucleoprotein K and suppresses hepatitis B virus expression.
    Cell Microbiol. 2008 Jan;10(1):112-21 PMID: 17672864
  15. A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor.
    Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3770-4 PMID: 14999100
  16. APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription.
    J Biol Chem. 2007 Nov 2;282(44):32065-74 PMID: 17855362
  17. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.
    Nature. 2002 Aug 8;418(6898):646-50 PMID: 12167863
  18. Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G.
    J Virol. 2006 Jan;80(2):875-82 PMID: 16378989
  19. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.
    Mol Cell. 2003 Sep;12(3):591-601 PMID: 14527406
  20. Selective inhibition of Alu retrotransposition by APOBEC3G.
    Gene. 2007 Apr 1;390(1-2):199-205 PMID: 17079095
  21. DNA deamination mediates innate immunity to retroviral infection.
    Cell. 2003 Jun 13;113(6):803-9 PMID: 12809610
  22. Association of human APOBEC3 cytidine deaminases with the generation of hepatitis virus B x antigen mutants and hepatocellular carcinoma.
    Hepatology. 2007 Dec;46(6):1810-20 PMID: 17847074
  23. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G.
    Curr Biol. 2003 Nov 11;13(22):2009-13 PMID: 14614829
  24. The innate antiretroviral factor APOBEC3G does not affect human LINE-1 retrotransposition in a cell culture assay.
    J Biol Chem. 2004 Oct 15;279(42):43371-3 PMID: 15322092
  25. Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors.
    J Virol. 2006 Feb;80(3):1067-76 PMID: 16414984
  26. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
    Nat Med. 2003 Nov;9(11):1404-7 PMID: 14528300
  27. Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor.
    Virology. 2004 Oct 25;328(2):163-8 PMID: 15464836
  28. Cellular inhibitors of long interspersed element 1 and Alu retrotransposition.
    Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8780-5 PMID: 16728505
  29. Model structure of human APOBEC3G.
    PLoS One. 2007 Apr 18;2(4):e378 PMID: 17440614
  30. Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G.
    FASEB J. 2007 Jan;21(1):217-22 PMID: 17135358
  31. APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism.
    J Biol Chem. 2006 Jun 23;281(25):16837-16841 PMID: 16648136
  32. APOBEC3 cytidine deaminases: distinct antiviral actions along the retroviral life cycle.
    J Biol Chem. 2006 Mar 31;281(13):8309-12 PMID: 16407183
  33. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.
    J Biol Chem. 2004 Aug 20;279(34):35822-8 PMID: 15210704
  34. Retrovirus restriction factors.
    Mol Cell. 2004 Dec 22;16(6):849-59 PMID: 15610729
  35. Retroviral restriction by APOBEC proteins.
    Nat Rev Immunol. 2004 Nov;4(11):868-77 PMID: 15516966
  36. Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication.
    J Virol. 2006 Dec;80(23):11710-22 PMID: 16971427
  37. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration.
    J Virol. 2007 Jul;81(13):7099-110 PMID: 17428871
  38. The APOBEC-2 crystal structure and functional implications for the deaminase AID.
    Nature. 2007 Jan 25;445(7126):447-51 PMID: 17187054
  39. HIV-1 and MLV Gag proteins are sufficient to recruit APOBEC3G into virus-like particles.
    Biochem Biophys Res Commun. 2004 Aug 27;321(3):566-73 PMID: 15358144
  40. Editing at the crossroad of innate and adaptive immunity.
    Science. 2005 Feb 18;307(5712):1061-5 PMID: 15718460
  41. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.
    Nature. 2003 Jul 3;424(6944):94-8 PMID: 12808465
  42. Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus.
    J Biol Chem. 2004 Oct 1;279(40):41744-9 PMID: 15297452
  43. Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C complex is essential for Vif function.
    J Biol Chem. 2005 May 13;280(19):18573-8 PMID: 15781449
  44. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
    J Virol. 2007 Aug;81(15):8201-10 PMID: 17522216
  45. A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action.
    J Biol Chem. 2004 Apr 9;279(15):14481-3 PMID: 14966139
  46. APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein.
    J Biol Chem. 2004 Aug 13;279(33):34083-6 PMID: 15215254
  47. APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase.
    Nucleic Acids Res. 2004 Apr 30;32(8):2421-9 PMID: 15121899
  48. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
    J Virol. 2006 Mar;80(6):3112-5 PMID: 16501124
  49. Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes.
    J Virol. 2005 May;79(9):5870-4 PMID: 15827203
  50. Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G.
    Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11444-9 PMID: 16076960
  51. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G.
    J Virol. 2004 Feb;78(4):2072-81 PMID: 14747572
  52. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation.
    Genes Dev. 2004 Dec 1;18(23):2861-6 PMID: 15574592
  53. Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant.
    J Virol. 2007 Aug;81(15):8236-46 PMID: 17522211
  54. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification.
    PLoS Pathog. 2005 Sep;1(1):e6 PMID: 16201018
  55. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
    Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5652-7 PMID: 15054139
  56. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.
    Science. 2003 Nov 7;302(5647):1056-60 PMID: 14564014
  57. Complementary function of the two catalytic domains of APOBEC3G.
    Virology. 2005 Mar 15;333(2):374-86 PMID: 15721369
  58. Production of infectious SIVagm from human cells requires functional inactivation but not viral exclusion of human APOBEC3G.
    J Biol Chem. 2005 Jan 7;280(1):375-82 PMID: 15528183
  59. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif.
    Cell. 2003 Jul 11;114(1):21-31 PMID: 12859895
  60. Recent insights into HIV-1 Vif.
    Curr Opin Immunol. 2004 Aug;16(4):477-82 PMID: 15245742
  61. Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif.
    Virology. 2006 Jun 5;349(2):290-9 PMID: 16530799
  62. APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons.
    Curr Biol. 2006 Mar 7;16(5):480-5 PMID: 16527742
  63. Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA.
    J Biol Chem. 2007 Apr 20;282(16):11667-75 PMID: 17272283
  64. Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase.
    J Virol. 2005 Aug;79(15):9579-87 PMID: 16014920
  65. Characterization of a novel Cullin5 binding domain in HIV-1 Vif.
    J Mol Biol. 2007 Oct 26;373(3):541-50 PMID: 17869271
  66. APOBEC3G incorporation into human immunodeficiency virus type 1 particles.
    J Virol. 2004 Nov;78(21):12058-61 PMID: 15479846
  67. High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition.
    Proc Natl Acad Sci U S A. 2006 Oct 17;103(42):15588-93 PMID: 17030807
  68. Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G.
    J Virol. 2006 Jun;80(12):5984-91 PMID: 16731937
  69. Natural resistance to HIV infection: The Vif-APOBEC interaction.
    C R Biol. 2006 Nov;329(11):871-5 PMID: 17067930
  70. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G.
    Nucleic Acids Res. 2007;35(21):7096-108 PMID: 17942420
  71. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.
    Nat Med. 2003 Nov;9(11):1398-403 PMID: 14528301
  72. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.
    J Virol. 2007 Jul;81(13):7238-48 PMID: 17428847
  73. A zinc-binding region in Vif binds Cul5 and determines cullin selection.
    J Biol Chem. 2006 Jun 23;281(25):17259-17265 PMID: 16636053
  74. 7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G.
    J Virol. 2007 Dec;81(23):13112-24 PMID: 17881443
  75. APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses.
    Nature. 2005 Jan 27;433(7024):430-3 PMID: 15674295
Article Info
Journal
Cellular microbiology
Abbr.
Cell Microbiol
ISSN
1462-5822
Published
2008-08-00
Epub
2008-00-16
Pages
1662-75
Language
English
Region
England
NLM ID
100883691
PMCID
PMC3086741
Subset
IM
Grants
NIAID NIH HHS · R21 AI071769 · United States
NIAID NIH HHS · R01 AI062644-04 · United States
NIAID NIH HHS · AI071769 · United States
NIAID NIH HHS · R56 AI062644 · United States
NIAID NIH HHS · AI062644 · United States
NIAID NIH HHS · R01 AI062644 · United States
NIAID NIH HHS · R21 AI071769-02 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com